France has agreed to partial reimbursement for the cost of Sanofi-Aventis' obesity drug Acomplia, but has placed some severe restrictions in its guidelines. The country will pay 35 percent of the cost of the drug, provided the patient is obese, has type 2 diabetes and meets certain blood sugar levels. In addition, only patients who have failed standard diabetic therapies and diet and exercise programs are covered. In France, drugs are partially reimbursed by the government, with employers covering all or a large part of the remaining bill.
- check out this article from the Acomplia Report